AAAmna Muhammad Ali

Amna Muhammad Ali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amna Muhammad Ali has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative Efficacy and Safety of Pulsed Field Ablation and Conventional Thermal Ablation for Atrial Fibrillation: A GRADE assessed Systematic Review and Meta analysis of Randomized Controlled Trials

    by Ahmad Hassan, Minahil Rasul, Kawish Nenwani, Mohammad Azeem Malik, Abdul Rehman Azam, Muhammad Abdur Rehman, Ubaid Ur Rehman, Intzar Ahmed, Qurrat Ul Ain Farooq, Amna Muhammad Ali, et al.

    Background Pulsed field ablation (PFA) is a nonthermal alternative to conventional thermal ablation (TA) for atrial fibrillation (AF), but comparative certainty across outcomes remains variable. Methods We systematically reviewed randomized controlled trials comparing PFA with radiofrequency or cryoballoon ablation. Primary analyses were restricted to paroxysmal AF; exploratory analyses incorporated trials enrolling persistent or mixed AF populations. Random-effects meta-analyses evaluated efficacy, safety, quality of life, and procedural outcomes, with certainty assessed using GRADE. Results Four RCTs (1,393 participants) contributed to the primary analyses. PFA did not differ from TA in atrial arrhythmia recurrence (RR 1.00, 95% CI 0.67–1.49) or single-procedure success (RR 1.04, 95% CI 0.92–1.17). Serious adverse events were also similar (RR 0.94, 95% CI 0.71–1.25). PFA significantly reduced skin-to-skin procedural time (MD −17.04 minutes, 95% CI −20.84 to −13.23). Exploratory analyses incorporating two additional RCTs generally supported these findings, including similar recurrence (RR 0.95, 95% CI 0.78–1.16) and single-procedure success (RR 1.06, 95% CI 0.99–1.13). Certainty ranged from moderate to very low across outcomes, with risk of bias, imprecision, and inconsistency contributing to downgrading. Conclusion PFA provides similar rhythm efficacy and overall safety to contemporary TA while reducing selected procedural times. However, confidence in individual estimates varies, particularly for rare complications and exploratory procedural outcomes. Further randomized evidence with longer follow-up is needed.

  • Open Access

    Efficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials

    by Affaf Mahmood, Noor Us Sehar, Aimen Farooq, Sajila Latif, Minahil Rasul, Shanza Abbasi, Amna Muhammad Ali, Eman Arshad, Mohammad Azeem Malik, Kawish Nenwani, et al.

    Background Mazdutide, a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist, has shown promising metabolic benefits in randomized controlled trials (RCTs) of adults with type 2 diabetes mellitus (T2DM). However, its efficacy and safety have not been systematically synthesized. Objective To evaluate the efficacy and safety of mazdutide versus placebo in adults with T2DM. Methods A systematic review and meta-analysis of RCTs was conducted according to PRISMA 2020 guidelines. PubMed, Embase, Cochrane Library, and ScienceDirect were searched from inception through May 2026. Risk of bias was assessed using the Cochrane RoB 2 tool, and certainty of evidence was evaluated with the GRADE framework. Results Three RCTs involving 613 participants were included. Compared with placebo, mazdutide significantly reduced HbA1c (MD −1.53%; 95% CI −1.70 to −1.35), body weight (MD −4.22%; 95% CI −5.71 to −2.73), fasting plasma glucose, body mass index, waist circumference, blood pressure, and triglycerides. It also increased the likelihood of achieving HbA1c <7.0% (OR 9.04; 95% CI 3.05–26.76) and ≥5% weight loss (OR 10.61; 95% CI 3.72–30.29). Treatment-emergent and gastrointestinal adverse events were more frequent with mazdutide, while severe treatment-emergent and serious adverse events did not differ significantly between groups. Certainty of evidence ranged from very low to high. Conclusions Mazdutide significantly improves glycemic control, weight, and cardiometabolic risk factors in adults with T2DM, with a generally manageable short-term safety profile primarily characterized by gastrointestinal adverse events. Larger, longer-term multicenter RCTs are needed to confirm these findings.